API
< Back to all clusters
[HEALTH] · United States · 2 sources

started · updated

Experimental malaria vaccine PfSPZ-LARC2 shows 87 percent efficacy

An experimental malaria vaccine, PfSPZ-LARC2, has demonstrated 87 percent efficacy in protecting participants against infection during an early clinical trial. The study, presented at the annual meeting of the American Society of Tropical Medicine and Hygiene, involved 22 volunteers who were subjected to controlled exposure to live malaria parasites.

Of the 15 participants who received the vaccine, only two contracted the infection. In contrast, all seven participants in the placebo group became infected. The vaccine utilizes genetically modified live malaria parasites that are unable to complete their life cycle in the human liver, thereby training the immune system to recognize and fight the parasite without causing disease.

The research was conducted with the University of Washington School of Medicine and Sanaria, under the sponsorship of the National Institute of Allergy and Infectious Diseases. While the results regarding safety and tolerability are encouraging, researchers noted that the trial was small and remains in the early stages. Further studies are required to determine long-term protection and efficacy against different parasite strains.

Entities

American Society of Tropical Medicine and Hygiene · National Institute of Allergy and Infectious Diseases · PfSPZ-LARC2 · Sanaria · University of Washington School of Medicine